Skip to main content
logo
Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
20.75
+1.04 (5.28%)
Aug 19, 2026, 4:00 PM EDT - Market closed

Avalo Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.060.060.441.9218.055.4
Revenue Growth
-86.62%-86.62%-77.08%-89.34%234.40%-19.42%
Gross Profit
-47.89-35.29-14.84-8.02-7.94-44.72
Operating Income
-91.36-72.93-40.87-23.44-29.94-82.13
Net Income
-100.33-78.26-35.13-31.54-41.66-84.38
Earnings Per Share
-4.18-5.84-20.91-113.58-1062.65-2331.41
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
400.2898.34134.557.4213.1754.59
Total Debt
0.240.430.921.921.6635.34
Net Cash (Debt)
400.0397.91133.635.51-8.4919.25
Net Cash Growth
255.32%-26.73%2324.31%--10.28%
Net Cash Per Share
16.657.3017.8319.85-216.49531.87

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-68.29-51.46-49.06-30.68-26.75-70.89
Capital Expenditures
----0.16-0.1-0.11
Free Cash Flow
-68.29-51.46-49.06-30.84-26.85-71.01
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-----43.98%-
Operating Margin
-154847.46%-123601.69%-9267.80%-1218.50%-165.86%-1521.56%
Pretax Margin
-169767.80%-132362.71%-7939.91%-1638.77%-230.62%-1566.23%
Profit Margin
-170055.93%-132642.37%-7965.76%-1639.50%-230.78%-1563.10%
FCF Margin
-115745.76%-87216.95%-11123.81%-1602.81%-148.72%-1315.39%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
18861.395581.57176.293.792.6335.37